German pharmaceutical firms Bayer and CureVac said Thursday that they have joined forces in the development of CureVac’s COVID-19 vaccine candidate.
Under the deal, CureVac will be able to tap Bayer’s expertise and established infrastructure, according to a joint statement.
Source: Read Full Article